One-and-Done gene shot could spare wet AMD patients from monthly eye needles
NCT ID NCT06196840
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a gene therapy called LX102 for wet age-related macular degeneration (nAMD), a leading cause of vision loss. The therapy is injected under the retina and aims to produce a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent anti-VEGF injections. About 50 adults aged 50–89 who have responded well to standard therapy are being studied to see if LX102 is safe and can maintain or improve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LX102 gene therapy (AAV-based VEGF-trap)
- What this could lead to
- If it works, this could allow people with wet AMD to need fewer anti-VEGF injections, controlling the disease with a single treatment.
- What could go wrong
- This is an early phase 2 trial with only 50 participants. Gene therapy carries risks like inflammation or retinal damage, and it may not reduce injection frequency for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Guangzhou Aier Eye Hospital
Guangzhou, China
-
Peking Union Medical College Hospital
Beijing, China
-
Shanghai Eye and ENT Hospital
Shanghai, China
-
Shanghai General Hospital
Shanghai, China
-
Shanxi Eye Hospital
Taiyuan, China
-
Tianjin Medical University Eye Hospital
Tianjin, China
-
West China Hospital of Sichuan University
Chengdu, China
-
Xuzhou No.1 People's Hospital
Xuzhou, China
-
Zhejiang University Eye Hospital
Hangzhou, Zhejiang, China
-
Zhongshan Ophthalmic Center of Sun Yat-Sen University
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection save vision in wet AMD?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- New eye drug aims to save sight in wet AMD
- Withdrawn study sought better way to time eye injections